GLP1R and Parkinson disease: Comparable to the SNpc of PD patients and the results of the latter study, post-mortem investigations revealed heightened GLP-1R mRNA levels in the hippocampus of AD patients and in vivo, likely as a countermeasure to reduce chronic inflammation, whereby GLP-1R was primarily exhibited by IBA-1-positive microglia (Park et al., 2021).